FIELD: medicine.
SUBSTANCE: invention relates to experimental hepatology, and can be used to correct metabolism in fatty liver disease of mixed genesis in the experiment. To do this, metformin is administered through the mouth to the rat at a dose of 300 mg/kg of animal body weight once a day for 30 days.
FFECT: increase in the effectiveness of the treatment of fatty liver disease of mixed genesis in the experiment.
1 cl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR MODELING FATTY LIVER DISEASE OF MIXED GENESIS IN RATS | 2020 |
|
RU2757199C1 |
METHOD OF SIMULATING NON-ALCOHOLIC FATTY LIVER DISEASE IN RATS | 2015 |
|
RU2600476C1 |
ANTYSTEATOSIS AGENT | 2019 |
|
RU2702003C1 |
METHOD OF MODELING NON-ALCOHOLIC STEATOHEPATITIS IN RATS | 2009 |
|
RU2394281C1 |
METHOD OF CORRECTING METABOLIC SYNDROME UNDER EXPERIMENTAL CONDITION | 2022 |
|
RU2806875C1 |
METHOD OF SIMULATING NON-ALCOHOLIC STEATOHEPATITIS IN RATS | 2015 |
|
RU2598351C1 |
APPLICATION OF Thr-Lys-Pro-Arg-Pro-Gly-Pro PEPTIDE (SELANK) FOR TOXIC HEPATITIS PREVENTION AND TREATMENT | 2017 |
|
RU2640133C1 |
METHOD FOR SIMULATING ACUTE LIVER DISEASE IN PREGNANT WOMEN | 2015 |
|
RU2610536C1 |
WAY TO TREAT LIVER CIRRHOSIS | 2022 |
|
RU2800017C1 |
AGENT FOR TREATMENT AND PROPHYLAXIS OF PATHOLOGICAL PROLIFERATION OF CONNECTIVE TISSUE IN PARENCHYMATOUS ORGANS | 1996 |
|
RU2146133C1 |
Authors
Dates
2023-04-03—Published
2022-02-10—Filed